CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AmiodaroneWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1730 PEEP trial Wiki 1.00
drug2635 Verapamil Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms

There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection.

NCT04351763 COVID-19 Drug: Amiodarone Drug: Verapamil

Primary Outcomes

Description: Time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7

Measure: Clinical improvement

Time: Randomization to day 15

Secondary Outcomes

Description: Time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7

Measure: Clinical improvement

Time: Randomization to day 7 and 28

Description: assessed on a seven category scale ranging from 1 to 7

Measure: Mean change in the 7-point ordinal scale

Time: Randomization to day 7,15 and 28

Description: Individual endpoint

Measure: Mortality

Time: Randomization to day 28

Description: Defined as body temperature (≤36.6°C [axilla], or ≤37.2 °C [oral], or ≤37.8°C [rectal]) for at least 48 hours without antipyretics or until discharge, whichever is sooner.

Measure: Time to resolution of fever

Time: Randomization to day 28

Description: Composite endpoint

Measure: Clinical improvement or fever resolution

Time: Randomization to day 7,15 and 28

Description: defined as atrial fibrillation, supraventricular or ventricular tachycardia requiring treatment

Measure: Tachyarrhythmias

Time: Randomization to day 28

Description: Composite endpoint

Measure: Mortality or tachyarrhythmias

Time: Randomization to day 28

Description: Clinical improvement assessed on a seven category scale ranging from 1 to 7.

Measure: Time to clinical improvement from admission using the 7-point ordinal scale

Time: Randomization to day 28

Description: The National Early Warning Score (NEWS2) score. A Higher score is worse.

Measure: Change in NEWS2 score

Time: Randomization to day 7 and 15

Measure: Duration of hospitalization

Time: Randomization to day 28

Description: oxygenation index defined as quotient of partial pressure of oxygen in arterial blood (PaO2, in mmHg) and fraction of inspired oxygen (FiO2)

Measure: PO2/FIO2

Time: Randomization to day 7 and 15

Description: Assessed on a modified seven category scale ranging from 1 to 7

Measure: Clinical improvement

Time: Randomization to day 15


No related HPO nodes (Using clinical trials)